TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group has received approval from the National Medical Products Administration for the domestic production and marketing authorization of its JP-1366 tablets, a potassium-competitive acid blocker aimed at treating reflux esophagitis. This development strengthens Livzon’s position in the gastrointestinal drug market, offering a new treatment option that has shown non-inferior results to existing medications in clinical trials, and aligns with the growing demand for P-CABs in China.
The most recent analyst rating on (HK:1513) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group is a company operating in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company is involved in creating medications for various medical conditions, with a particular emphasis on gastrointestinal treatments.
Average Trading Volume: 2,301,342
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$36.82B
For a thorough assessment of 1513 stock, go to TipRanks’ Stock Analysis page.